CD8A and neoplasm: CD4+ and CD8+ T cells that were specific for a wide range of NY-ESO-1 epitopes were also observed in the peripheral, highlighting the potential use of NY-ESO-1 IMX vaccine in various NY-ESO-1 positive tumours [109].